STOCK TITAN

Zevra Therapeutics, Inc. - $ZVRA STOCK NEWS

Welcome to our dedicated page for Zevra Therapeutics news (Ticker: $ZVRA), a resource for investors and traders seeking the latest updates and insights on Zevra Therapeutics stock.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect Zevra Therapeutics's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of Zevra Therapeutics's position in the market.

Rhea-AI Summary
Zevra Therapeutics supports the Niemann-Pick community on Global Niemann-Pick Disease Awareness Day and throughout Niemann-Pick Disease Awareness Month.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
Zevra Therapeutics announces Neil F. McFarlane as new CEO, Christal M.M. Mickle transitions back to Chief Development Officer.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.81%
Tags
management
-
Rhea-AI Summary
Zevra Therapeutics to present data on arimoclomol program for Niemann-Pick Disease type C at 52nd CNS Annual Meeting
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
conferences
Rhea-AI Summary
Zevra Therapeutics (ZVRA) announces positive interim data from Phase 2 trial of KP1077 for idiopathic hypersomnia, indicating well-tolerated doses and potential benefits compared to current treatments. Topline data expected in H1 2024. Anticipated Phase 3 trial to be initiated by end of 2024.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.07%
Tags
-
Rhea-AI Summary
Zevra Therapeutics to participate in Cantor Global Healthcare Conference on September 27, 2023
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-2.95%
Tags
conferences
-
Rhea-AI Summary
Zevra Therapeutics presents study data on cardiovascular safety of serdexmethylphenidate (SDX) for idiopathic hypersomnia treatment
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
Rhea-AI Summary
Zevra Therapeutics to present at H.C. Wainwright conference
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.51%
Tags
conferences
-
Rhea-AI Summary
Zevra to acquire Acer in a merger transaction valued at up to $91 million, increasing Zevra's rare disease portfolio and diversifying revenues with OLPRUVA™ commercial asset. Zevra also adds EDSIVO™ to rare disease clinical pipeline. The merger is subject to approval by Acer's stockholders. Expected closing in Q4 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-4.34%
Tags
-
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
3.85%
Tags
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
7%
Tags
management
Zevra Therapeutics, Inc.

Nasdaq:ZVRA

ZVRA Rankings

ZVRA Stock Data

197.97M
36.09M
8.08%
29.7%
5.38%
Pharmaceutical Preparation Manufacturing
Manufacturing
Link
United States of America
CELEBRATION

About ZVRA

kempharm is a biopharmaceutical company focused on the discovery and development of new chemical entities (nces) to treat serious medical conditions through its proprietary and broadly applicable ligand activated therapy (lat) approach. the company utilizes its lat technology to generate improved prodrug versions of fda approved drugs in the high needs areas of pain, adhd and other cns diseases.